O Rachid, M Rawas-Qalaji, FER Simons… - AAPS PharmSciTech, 2011 - Springer Received 22 December 2010; accepted 4 April 2011 Abstract. In the sublingual (SL) cavity, compared with the gastrointestinal tract, tablets are subjected to minimal physiological agitation, and a limited volume of saliva is available to facilitate disintegration and dissolution. None of the official ... Related articles - All 2 versions
[HTML] from nih.govF Ibrahim, MKS El-Din, MI Eid… - Chemistry Central …, 2011 - ncbi.nlm.nih.gov An accurate, simple, sensitive and selective reversed phase liquid chromatographic method has been developed for the determination of ebastine in its pharmaceutical preparations. The proposed method depends on the complexation ability of the studied drug with Zn 2+ ... Cited by 1 - Related articles - All 4 versions
[HTML] from thelancet.itG Giovannoni, S Cook, K Rammohan… - The Lancet …, 2011 - Elsevier On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing–remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of ... Cited by 4 - Related articles - All 5 versions
[HTML] from pediatricsdigest.mobiSH Kollins, R Jain, M Brams, S Segal… - …, 2011 - pediatricsdigest.mobi RESULTS: Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale IV (ADHD-RS-IV) total score (95% confidence interval: −7.83 to −1.13; P = .009), ... Cited by 2 - Related articles - All 4 versions
S Cook, P Vermersch, G Comi… - Multiple Sclerosis …, 2011 - msj.sagepub.com ... Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. ... Results: Of the randomized patients, 88.6% completed treatment with cladribine tablets versus 86.3% with placebo. ... Cited by 3 - Related articles - All 3 versions
O Rachid, M Rawas-Qalaji, FER Simons… - AAPS PharmSciTech, 2011 - Springer Received 22 December 2010; accepted 4 April 2011 Abstract. In the sublingual (SL) cavity, compared with the gastrointestinal tract, tablets are subjected to minimal physiological agitation, and a limited volume of saliva is available to facilitate disintegration and dissolution. None of the official ... Related articles - All 2 versions
[HTML] from nih.govF Ibrahim, MKS El-Din, MI Eid… - Chemistry Central …, 2011 - ncbi.nlm.nih.gov An accurate, simple, sensitive and selective reversed phase liquid chromatographic method has been developed for the determination of ebastine in its pharmaceutical preparations. The proposed method depends on the complexation ability of the studied drug with Zn 2+ ... Cited by 1 - Related articles - All 4 versions
[HTML] from thelancet.itG Giovannoni, S Cook, K Rammohan… - The Lancet …, 2011 - Elsevier On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing–remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of ... Cited by 4 - Related articles - All 5 versions
[HTML] from pediatricsdigest.mobiSH Kollins, R Jain, M Brams, S Segal… - …, 2011 - pediatricsdigest.mobi RESULTS: Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale IV (ADHD-RS-IV) total score (95% confidence interval: −7.83 to −1.13; P = .009), ... Cited by 2 - Related articles - All 4 versions
S Cook, P Vermersch, G Comi… - Multiple Sclerosis …, 2011 - msj.sagepub.com ... Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. ... Results: Of the randomized patients, 88.6% completed treatment with cladribine tablets versus 86.3% with placebo. ... Cited by 3 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
